Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia

Blood Cancer Journal
W JangY Kim

Abstract

KIT exon 17 mutation is a poor prognostic factor in core-binding factor acute myeloid leukemia. However, the mutation detection method used for risk assessment is not assigned. It is necessary to verify the analytical and clinical performance before applying new methods. Herein, we firstly applied a highly sensitive allele-specific, real-time quantitative PCR (AS-qPCR) assay to analyze KIT mutations, which demonstrated excellent sensitivity and specificity. Much higher incidence of KIT mutations (62.2%, 69/111) and prevalence of multiple mutations (43.5%, 30/69) were observed using AS-qPCR, which meant the existence of multiple KIT mutant subclones. The relative KIT mutant level was variable (median, 0.3 per control allele 100 copies, 0.002-532.7) and was divided into two groups: high (⩾10, n=26) and low (<10) mutant level. Interestingly, rather than mutation positivity, mutant level was found to be associated with clinical outcome. High mutant level showed significantly inferior overall survival (P=0.005) and event-free survival (P=0.03), whereas low level did not influence the prognosis. The follow-up data showed that the mutant level were along with fusion transcripts in the majority (n=29), but moved separately in some case...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonM J Keating
Sep 19, 2001·Current Opinion in Hematology·D G Gilliland
Sep 21, 2001·Current Opinion in Hematology
Jan 15, 2005·Proceedings of the National Academy of Sciences of the United States of America·Yue-Ying WangSai-Juan Chen
Apr 7, 2006·Leukemia·N BoisselUNKNOWN Leucémies Aiguës Myéloblastiques de l'Enfant (LAME) Cooperative Groups
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaUNKNOWN Cancer and Leukemia Group B
Jul 1, 2011·Leukemia Research·Sang Hyuk ParkChan-Jeoung Park
Oct 8, 2011·The Journal of Molecular Diagnostics : JMD·Seung-Tae LeeChang-Seok Ki
Oct 13, 2012·British Journal of Haematology·Anthony J BenchUNKNOWN British Committee for Standards in Haematology
Nov 7, 2012·Expert Opinion on Investigational Drugs·Leonie K Ashman, Renate Griffith
Mar 8, 2013·Oncology Reports·Ludovica RieraAchille Pich

❮ Previous
Next ❯

Citations

Feb 15, 2019·Laboratory Investigation; a Journal of Technical Methods and Pathology·Richard J KarpowiczVirginia M-Y Lee

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
Genotyping
Assay

Software Mentioned

SPSS
Pyrosequencing Assay Design

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.